戻る
Apellis Pharmaceuticals Reports Mixed Q2 Results Amidst Key FDA Approval
戻る
株式ニュース
テーマ
Apellis Pharmaceuticals Reports Mixed Q2 Results Amidst Key FDA Approval
遺伝子編集
Apellis Pharmaceuticals Reports Mixed Q2 Results Amidst Key FDA Approval
Edgen Stock
·
Sep 30 2025, 10:51
共有先
共有先
リンクをコピー
ソース：
[1] Wall Street Has a Mixed Opinion on Apellis Pharmaceuticals (APLS)
[2] Wall Street Has a Mixed Opinion on Apellis Pharmaceuticals (APLS) - Insider Monkey
[3] Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results - Stock Titan
Edgen Stock·Sep 30 2025, 10:51Edgen Stock·Sep 30 2025, 10:51
Edgen Stock·Sep 30 2025, 10:51